Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-4.25% $4.06
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 240.56 mill |
EPS: | -3.30 |
P/E: | -1.230 |
Earnings Date: | Mar 25, 2024 |
SharesOutstanding: | 59.25 mill |
Avg Daily Volume: | 4.02 mill |
RATING 2024-04-25 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.230 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.21x |
Company: PE -1.230 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.667 (-83.56%) $-3.39 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 3.35 - 4.77 ( +/- 17.54%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Subramaniam Somu | Sell | 695 339 | Common Stock |
2024-04-12 | Nsv Partners Iii Lp | Sell | 695 339 | Common Stock |
2024-04-02 | Krueger Christopher W | Sell | 1 651 | Common Stock |
2024-04-02 | Nuss John | Sell | 1 651 | Common Stock |
2024-04-02 | Mohan Raju | Sell | 4 312 | Common Stock |
INSIDER POWER |
---|
-9.36 |
Last 100 transactions |
Buy: 2 083 814 | Sell: 2 354 020 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.06 (-4.25% ) |
Volume | 0.560 mill |
Avg. Vol. | 4.02 mill |
% of Avg. Vol | 13.92 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $2.35 | N/A | Active |
---|
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.